✓
Open
20 Dec 2024
✓
Close
24 Dec 2024
3
Allotment
—
✓
Listing
Mon, Dec 30, 2024
Price Band
₹372 to ₹391
Issue Size
1,48,87,723 shares (agg. up to ₹582 Cr)
Lot Size
38 Shares
Listing Date
Mon, Dec 30, 2024
Latest GMP
₹284
Est. Gain
72.63%
✦ AI Insight
GMP Trend
30-12-2024₹284Est. ₹675+72.63%
29-12-2024₹284Est. ₹675+72.63%
28-12-2024₹284Est. ₹675+72.63%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 54.02x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| NET Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,272.00 (-1.60%) |
| Akums Drugs & Pharmaceuticals Ltd. | Mainboard | ₹1,856.74 Cr | ₹679 | null | ₹796.25 | +17.27% | ₹664.95 (-2.60%) |
| Emcure Pharmaceuticals Ltd. | Mainboard | ₹1,952.03 Cr | ₹1008 | 34.55 | ₹1,359.15 | +34.84% | ₹1,783.20 (-1.07%) |
| Innova Captab Ltd. | Mainboard | ₹570.00 Cr | ₹448 | 31.64 | ₹541.40 | +20.85% | ₹962.70 (-4.76%) |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹37.60 (-4.93%) |
| Medicamen Organics Ltd. | SME | ₹10.54 Cr | ₹34 | 30.53 | ₹144.70 | +325.59% | ₹22.90 (-0.43%) |
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹94.50 (-2.53%) |
| Zenith Drugs Ltd. | SME | ₹40.68 Cr | ₹79 | 18.4 | ₹105.15 | +33.10% | ₹51.00 (+1.80%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | 107.00 |
| 2 | Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company | 73.48 |
| 3 | Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | 20.22 |
| 4 | Funding the working capital requirements of the Company | 43.26 |
| 5 | Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements | 59.48 |
| 6 | Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes | 154.37 |
About Senores Pharmaceuticals IPO
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets. The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets. As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India. As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US. The
Contact Details
Senores Pharmaceuticals Ltd. Address1101 to 1103, 11th floorSouth Tower, ONE 42 oppositeJayantilal ParkAmbali Bopal RoadAhmedabad, Gujarat, 380054+91-79-29999857cs@senorespharma.comVisit Website